We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

INBIOS INTERNATIONAL

InBios International, Inc. is a biotechnology company specializing in the design, development and manufacture of immu... read more Featured Products: More products

Download Mobile App




Anti-Dengue Virus IgM Detected in Urine

By LabMedica International staff writers
Posted on 20 Feb 2020
Dengue viruses (DENV) are transmitted to humans by infected mosquitoes and the disease, known as dengue, occurs throughout the tropics and subtropics. More...
Dengue diagnostic tests rely on a blood sample taken within two weeks of illness onset.

Dengue initially presents as an acute febrile illness (AFI) that can be difficult to diagnose clinically and differentiate from other AFIs such as malaria, leptospirosis, influenza, and chikungunya; however, even if dengue is suspected and diagnosed early, a patient’s clinical course and outcome is unpredictable.

Scientists at the University of Puerto Rico (San Juan, Puerto Rico) and their colleagues used specimens collected from 1,538 study participants enrolled between May 2012-March 2013, of an AFI study conducted in Ponce, Puerto Rico. Study participants with fever for ≤7 days were enrolled, a medical history was obtained, and serum and urine specimens were collected.

Serum specimens collected ≤6 days post-illness onset (DPO) were tested by real-time reverse transcription polymerase chain reaction (rRT-PCR ) to detect DENV nucleic acid as previously described. Serum specimens collected ≥4 DPO were tested for the presence of anti-DENV IgM by DENV Detect IgM ELISA (InBios International, Inc., Seattle, WA, USA). Urine was tested for anti-DENV IgM, and its sensitivity and specificity to detect sera laboratory-positive dengue cases were calculated. The team evaluated if urine anti-DENV IgM positivity early (≤5 days DPO) and late (6–14 DPO) in the clinical course was associated with dengue severity.

The scientists reported that urine anti-DENV IgM sensitivity and specificity were 47.4% and 98.5%, respectively, when compared with serum anti-DENV IgM ELISA results, and 29.7% and 91.1% when compared with serum rRT-PCR results. There was no correlation between urine anti-DENV IgM positivity and patient sex or pre-existing chronic disease. Early in the clinical course, a significantly higher proportion of those who developed dengue with warning signs had anti-DENV IgM in their urine when compared to those without warning signs (20.4% versus 4.3%). There was no difference in the proportion with urine anti-DENV IgM positivity between severity groups late in the clinical course.

The authors concluded that the use of urine as a surrogate specimen for dengue diagnosis was not sensitive in comparison to serum; however, the presence of anti-DENV IgM urine was highly specific. They were able to identify the presence of anti-DENV IgM in urine specimens from laboratory-positive dengue cases using a simple diagnostic assay. This assay may prove to be useful as a diagnostic tool as well as a prognostic tool to differentiate dengue from dengue with warning signs early in the course of illness (DPO<5). The study was published on January 29, 2020 in the journal PLOS Neglected Tropical Diseases.

Related Links:
University of Puerto Rico
InBios International



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.